Clinical trials: Aldosterone Disorder
Hypertension, Primary Aldosteronism
Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone
This is an observational study compares the positivity rates of two tests for screening for primary aldosteronism: plasma aldosterone renin ratio and 24-hour urine aldosterone in patients with young-onset hypertension with or…
- Conditions
- Hypertension, Primary Aldosteronism, Urine Aldosterone
- Trial name
- PURL (NCT06047912)
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Dr Ian B Wilkinson
Metabolic Syndrome X
Diurnal Variation of Plasminogen Activator Inhibitor-1
To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
- Trial name
- NCT00515021
- Testing
- Eplerenone (Morning), Eplerenone (Night-time)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Vanderbilt University Medical Center
Postural Tachycardia Syndrome
Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening
The purpose of the study is to determine whether patients meet criteria for Postural Tachycardia Syndrome (or not) and have reduced blood volume (or not).
- Trial name
- NCT01783288
- Testing
- Autonomic Function Testing, Posture Study, Measurement of Total Blood Volume
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Genetics in Hypertension
Beta-2 Adrenergic Receptor Polymorphic Variants: An Endotype of Salt Sensitive Hypertension (Beta2AR).
All living things are made of building blocks called cells. Genes are the part of cells that contain the instructions which determine important things about you, like your height or hair color, and affect your health.
- Trial name
- Beta2AR (NCT07832942)
- Testing
- low sodium diet, high sodium diet, renal plasma flow
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Brigham and Women's Hospital
Tetralogy of Fallot, Heart Defects, Congenital
Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System
Rationale: The prevalence of adult patients with congenital heart disease (CHD) has steadily increased over the last decades, due to the advances in cardiac surgery.
- Conditions
- Tetralogy of Fallot, Heart Defects, Congenital, Ventricular Dysfunction, Right
- Trial name
- Redefine (NCT02010905)
- Testing
- Losartan
- Where
- 6 sites in Netherlands
- Volunteers
- 120 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Diabetic Nephropathy
Spironolactone in Diabetic Nephropathy
The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d.
- Trial name
- NCT00317954
- Testing
- Spironolactone
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Steno Diabetes Center Copenhagen
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
10% of patients with hypertension potentially have the treatable condition - primary aldosteronism (PA). This is caused by either bilateral adrenal disease (~40%), managed with lifelong medications; or unilateral disease (~60%)…
- Conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, Adrenal Tumors
- Trial name
- NCT06100367
- Testing
- 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
- Where
- 7 sites in Singapore
- Volunteers
- 97 people
- Sponsor
- Changi General Hospital
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy
Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients
Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAAS blockade (total daily dose…
- Conditions
- Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria
- Trial name
- NCT00961207
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cook County Health
HIV
Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)
HIV-infected individuals treated with antiretroviral medications are living longer, but have an increased risk of heart disease when compared to non-HIV-infected individuals.
- Trial name
- NCT02740179
- Testing
- Eplerenone, Lifestyle Modification
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes Mellitus
The Effect of Uric Acid Lowering in Type 1 Diabetes
Patients with type 1 diabetes mellitus (T1DM) are at high risk of developing kidney complications potentially leading to end stage renal disease.
- Trial name
- NCT02344602
- Testing
- Febuxostat
- Where
- Canada
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Myocardial Infarction
Aldosterone Blockade Early After Acute Myocardial Infarction
Study hypothesis : An early blockade of aldosterone receptors initiated at the first medical contact after acute myocardial infarction may reduce major cardiovascular events within 6 months after the occurrence of the myocardial…
- Trial name
- ALBATROSS (NCT01059136)
- Testing
- Spironolactone
- Where
- France
- Volunteers
- 1,603 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Aldosteronism, Endocrine Hypertension
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism
The goal of this pilot, open-label prospective study is to evaluate if the effect of calcium channel blockade on plasma aldosterone levels in people with primary aldosteronism (PA) is due primarily to Cav1.3 blockade.
- Trial name
- NCT05686993
- Testing
- Cinnarizine, NIFEdipine ER
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Queen Mary University of London
Heart Failure
Aldosterone Blockade in Heart Failure
Heart failure causes significant morbidity and mortality and is the most rapidly increasing cardiovascular diagnosis in North America overall prevalence is estimated at 0.4% to 2.4%.
- Trial name
- ARCTIC-D (NCT00523757)
- Testing
- Spironolactone
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Justin Ezekowitz
Apnea, Obstructive
EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION
Obstructive sleep apnea syndrome (OSAS) is associated with hyperaldosteronism with elevated plasma aldosterone/renin ratio, the physiopathological mechanism of which remains uncertain.
- Trial name
- APHOS3 (NCT06462287)
- Testing
- Aprepitant 125 and 80Mg Oral Capsule
- Where
- France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Rouen
Sleep Apnea, Arrhythmias, Cardiac
Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction
Little is known about potential relationships between sleep apnea, plasma aldosterone and diastolic dysfunction which is a very frequent finding among patients requiring permanent cardiac pacing.
- Conditions
- Sleep Apnea, Arrhythmias, Cardiac, Cardiac Diastolic Function, Hyperaldosteronism
- Trial name
- SAPAAD (NCT02751021)
- Testing
- pacemaker diagnostic algorithm, Attended cardiorespiratory sleep study
- Where
- France
- Volunteers
- 66 people
- Sponsor
- University Hospital, Caen
Primary Aldosteronism
Baxdrostat and Molecular Imaging of Adrenal Cytoreduction in Primary Aldosteronism
The goal of this clinical trial is to find out whether treatment with baxdrostat changes aldosterone-producing activity in the adrenal glands of people with primary aldosteronism.
- Trial name
- EliXir (NCT07800858)
- Testing
- baxdrostat
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Queen Mary University of London
Kidney, Polycystic
HALT Progression of Polycystic Kidney Disease Study A
The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two…
- Trial name
- HALT PKD A (NCT00283686)
- Testing
- Lisinopril, Telmisartan, Standard Blood Pressure Control
- Where
- 7 sites in United States
- Volunteers
- 558 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Transposition of Great Vessels, Atrial Switch Procedure
Eplerenone in Systemic Right Ventricle
BACKGROUND: There is no clinical evidence supporting medical treatment for the failing systemic right ventricle in patients with transposition of the great vessels with atrial switch.
- Trial name
- EVEDES (NCT00703352)
- Testing
- Eplerenone
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Ovarian Hyperstimulation Syndrome
Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response
lines of evidence that support nature of ovarian hyperstimulation syndrome (OHSS) as "defective mineralocorticoid response" are cited, our hypothesis is tested clinically in both prophylaxis against and treatment of OHSS.
- Trial name
- NCT04351126
- Testing
- Fludrocortisone 0.1 Milligrams (mg), Bromocriptine
- Where
- Egypt
- Volunteers
- 107 people
- Sponsor
- Ganin Fertility Center
Primary Aldosteronism
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.
- Trial name
- NCT07646535
- Testing
- SAL0140 Tablets
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.